bpc 157 delivery method BPC-157 Peptide Therapy Multifunctionality and Possible Medical Application

Feig DI, Soletsky B, Johnson RJ

FDA reviewers, applying the statutory framework under 21 CFR 216.23(c), identified only one human study for BPC-157's proposed indication of ulcerative colitis: a decades-old meeting abstract that was never published as a peer-reviewed trial and that used an oral route of administration not the injectable or subcutaneous routes that wellness clinics commonly use

Together, BPC-157 and TB-500 work synergistically to increase the quantity and function of actin and thus increase the rate at which fibroblasts and cells of the immune system migrate to areas of injury

That makes it the most cost-effective vial size for most researchers